Get the Stockscreener App
22.58
4.12%
-0.97
After Hours:
22.75
0.17
+0.75%
Dyne Therapeutics Inc stock is traded at $22.58, with a volume of 3.00M.
It is down -4.12% in the last 24 hours and up +78.50% over the past month.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
See More
Previous Close:
$23.55
Open:
$23.21
24h Volume:
3.00M
Relative Volume:
1.08
Market Cap:
$3.21B
Revenue:
-
Net Income/Loss:
$-412.89M
P/E Ratio:
-5.8497
EPS:
-3.86
Net Cash Flow:
$-361.93M
1W Performance:
+31.89%
1M Performance:
+78.50%
6M Performance:
+91.52%
1Y Performance:
-21.76%
1-Day Range:
$22.23
$23.34
1-Week Range:
$22.23
$25.00
52-Week Range:
$6.36
$35.68
Dyne Therapeutics Inc Stock (DYN) Company Profile
Name
Dyne Therapeutics Inc
Sector
Industry
Phone
(781) 786-8230
Address
1560 TRAPELO ROAD, WALTHAM
Compare DYN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
22.58 | 3.35B | 0 | -412.89M | -361.93M | -3.86 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | -52.09M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-25-25 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jun-24-25 | Initiated | Bernstein | Mkt Perform |
| Jun-11-25 | Resumed | Raymond James | Outperform |
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-29-25 | Initiated | Evercore ISI | Outperform |
| Mar-12-25 | Initiated | BMO Capital Markets | Outperform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-13-24 | Initiated | Robert W. Baird | Outperform |
| Nov-26-24 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-24 | Downgrade | JP Morgan | Overweight → Neutral |
| May-21-24 | Reiterated | Chardan Capital Markets | Buy |
| Apr-30-24 | Initiated | Morgan Stanley | Overweight |
| Feb-20-24 | Initiated | H.C. Wainwright | Buy |
| Feb-27-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Feb-15-23 | Initiated | Oppenheimer | Outperform |
| Jan-26-23 | Initiated | Guggenheim | Buy |
| Jul-20-22 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-22 | Initiated | Raymond James | Outperform |
| Oct-12-20 | Initiated | JP Morgan | Overweight |
| Oct-12-20 | Initiated | Jefferies | Buy |
| Oct-12-20 | Initiated | Piper Sandler | Overweight |
| Oct-12-20 | Initiated | Stifel | Buy |
View All
Dyne Therapeutics Inc Stock (DYN) Latest News
Analyzing Dyne Therapeutics Inc. with risk reward ratio charts2025 Trading Volume Trends & Accurate Trade Setup Notifications - newser.com
Dyne Therapeutics Inc.’s volatility index tracking explainedRate Hike & Low Drawdown Investment Strategies - newser.com
Can trapped investors hope for a rebound in Dyne Therapeutics Inc.Weekly Trend Report & Fast Moving Market Watchlists - newser.com
Is Dyne Therapeutics Inc. stock entering bullish territory2025 Top Gainers & Reliable Volume Spike Alerts - newser.com
Technical analysis overview for Dyne Therapeutics Inc. stock2025 Technical Patterns & Low Drawdown Investment Ideas - newser.com
Using RSI to spot recovery in Dyne Therapeutics Inc.2025 Winners & Losers & Technical Entry and Exit Tips - newser.com
Is Dyne Therapeutics Inc. reversing from oversold territoryPortfolio Value Summary & Fast Exit and Entry Strategy Plans - newser.com
Is Dyne Therapeutics Inc. stock gaining market share2025 Investor Takeaways & Stock Portfolio Risk Management - newser.com
What recovery options are there for Dyne Therapeutics Inc.Market Risk Analysis & Low Volatility Stock Suggestions - newser.com
Why Dyne Therapeutics Inc. stock is seen as undervaluedGDP Growth & Stock Portfolio Risk Control - newser.com
Will Dyne Therapeutics Inc. stock deliver better than expected guidance2025 Dividend Review & Safe Capital Investment Plans - newser.com
Sector ETF performance correlation with Dyne Therapeutics Inc.Weekly Risk Summary & AI Powered Market Trend Analysis - newser.com
Historical volatility pattern of Dyne Therapeutics Inc. visualizedMarket Growth Summary & Real-Time Volume Analysis - newser.com
How moving averages guide Dyne Therapeutics Inc. trading2025 Year in Review & Stock Timing and Entry Methods - newser.com
Is Dyne Therapeutics Inc. stock a bargain at current levels2025 Geopolitical Influence & Reliable Breakout Stock Forecasts - newser.com
Qualcomm, Tesla, Intellia Therapeutics, Avidity Biosciences, Dyne Therapeutics: Stocks Making The Biggest Moves Today - MSN
Dyne Therapeutics Stock Soars After Rival Avidity Biosciences Gets Acquired By Novartis - MSN
Can you recover from losses in Dyne Therapeutics Inc.Recession Risk & AI Forecast Swing Trade Picks - newser.com
Dyne Therapeutics (NASDAQ:DYN) Shares Gap UpStill a Buy? - MarketBeat
10 Big Names Crushing Wall Street - Insider Monkey
Dyne (DYN) Jumps 41% as Jefferies Bets Firm to Benefit from Novartis-Avidity Merger - Insider Monkey
Dyne Therapeutics Inc Stock (DYN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):